FOXA1 and metabolic disease: However, recent studies have shown that miR‐194 suppresses GLP‐1 synthesis by inhibiting the expression of the Wnt signaling effector beta‐catenin and the forkhead box a1 (Foxa1) protein, suggesting a role for miRNAs in the modulation of glucagon‐like peptide signaling with potential implications for the management of obesity and metabolic disorders [69].